Advertisement

Advertisement

gastroesophageal cancer

Yoon-Koo Kang, MD, PhD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Trial Results for T-DM1 vs a Taxane

Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (Abstract 5).

gastroesophageal cancer

Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).

gastroesophageal cancer

Somnath Mukherjee, MD, on Esophageal Adenocarcinoma: Results of the NEOSCOPE Trial

Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based chemoradiation as a pre-operative regimen for resectable esophageal cancer.. (Abstract 3).

gastroesophageal cancer

Toshihiko Doi, MD, PhD, on Esophageal Carcinoma: Study Results From KEYNOTE-028

Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).

gastroesophageal cancer
issues in oncology
issues in oncology

STS 2016: Race, Lower Socioeconomic Status Linked With Worse Survival Following Esophageal Cancer Surgery

Poor black patients undergoing surgery for esophageal cancer are at higher risk for death than white patients and patients with higher socioeconomic status, according to a scientific presentation by Erhunmwunsee et al at the 52nd Annual Meeting of The Society of Thoracic Surgeons. The abstract,...

Gastroesophageal Cancer

Preoperative Chemoradiotherapy May Extend Survival for Patients with Esophagogastric Junction Adenocarcinoma

Several American and European clinical trials have yielded mixed results on the survival advantage of preoperative chemoradiotherapy for patients with locally advanced esophagogastric junction adenonocarcinoma. However, a distinguished panel at the 2011 ASTRO Annual Meeting did agree that surgery...

Gastroesophageal Cancer

Most Hospitals Do Not Meet Benchmark for Examining Lymph Nodes following Esophagectomy

“Fewer than one-third of patients and fewer than 1 in 10 hospitals met the benchmark of examining at least 15 lymph nodes” following esophagectomy for patients with esophageal cancer, according to a retrospective observational study reported in the Archives of Surgery. That benchmark was set by the ...

Solid Tumors
Gastroesophageal Cancer

Second-line Docetaxel Improves Esophageal and Gastric Cancer Survival 

A phase III study from the United Kingdom has shown that second-line treatment with docetaxel improves overall survival of patients with advanced esophagogastric cancer.1 The strategy has already been widely adopted, but COUGAR-02 is the first study to provide definitive evidence of a survival...

Breast Cancer
Skin Cancer
Multiple Myeloma
Supportive Care
Gastroesophageal Cancer

New Research Presented in Breast, Gastric, Esophageal Cancers, Melanoma, and Multiple Myeloma, plus Supportive Care 

Attendees at the ASCO Annual Meeting are faced with a major challenge of trying to attend as many important sessions as they can over a 4-day period. Our challenge is to feature the major news in The ASCO Post. In addition to our regular comprehensive coverage of key presentations, the following...

Gastroesophageal Cancer
Gastrointestinal Cancer

Anti–VEGFR-2 Antibody Ramucirumab Prolongs Survival in Previously Treated Advanced Gastric or Gastroesophageal Cancer

Vascular endothelial growth factor (VEGF)– and VEGF receptor-2 (VEGFR-2)–mediated signaling and angiogenesis seem to have an important role in the pathogenesis of gastric cancer. In the phase III REGARD trial reported in Lancet, Charles S. Fuchs, MD, MPH, of Dana-Farber Cancer Institute, Boston,...

Gastroesophageal Cancer

Cetuximab Fails to Improve Survival in Nonoperable Esophageal Cancer

More data have emerged that discount the potential for benefit with epidermal growth factor receptor (EGFR) inhibitors in esophageal cancer. The latest comes from the RTOG 0436 randomized phase III trial in patients with nonoperable esophageal cancer, the results of which were presented at the 2014 ...

Gastroesophageal Cancer

Ramucirumab for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

On April 21, 2014, ramucirumab (Cyramza) was approved for use as a single agent in the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing...

Gastroesophageal Cancer

Rilotumumab Added to First-Line Chemotherapy May Benefit Patients With Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Hepatocyte growth factor (HGF) and its receptor MET have been found to promote the proliferation, migration, and survival of tumor cells and to play a role in gastric cancer. In a phase II study reported in The Lancet Oncology, Timothy Iveson, MD, of the University Hospital Southampton NHS...

Gastroesophageal Cancer

IGF-2/IGF-1R Inhibition Shows Promise in Esophageal Cancer

In a study reported in Clinical Cancer Research, Li and colleagues found that overexpression of Id1 protein resulted in insulin-like growth factor (IGF)-2 production, which, in turn, resulted in esophageal cancer cell proliferation, survival, and invasion via autocrine activation of AKT....

Gastroesophageal Cancer

EGFR as a Therapeutic Target for Gastroesophageal Cancer—or Is It Really?

The epidermal growth factor receptor (EGFR) gene is often amplified and its protein overexpressed in upper gastrointestinal cancers—and overexpression has prognostic value. With the advent of monoclonal antibodies and tyrosine kinase inhibitors against EGFR, we have witnessed a rash of randomized...

Gastroesophageal Cancer
Palliative Care

No Overall Survival Improvement but Some Palliative Benefit With Gefitinib in Esophageal Cancer Progressing Postchemotherapy

In what may be the first randomized trial of systemic therapy in this setting, Susan J. Dutton, MSc, of University of Oxford, United Kingdom, and colleagues evaluated the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib vs placebo in patients with esophageal cancer...

Breast Cancer
Gastroesophageal Cancer

TRIM44 Amplification in Esophagogastric, Breast Tumors May Be Marker for mTOR Inhibitor Therapy

TRIM44 family overexpression is associated with carcinogenesis, and TRIM44 has been identified as a prognostic gene. In a study reported in Journal of the National Cancer Institute, Ong and colleagues attempted to identify therapeutic strategies for patients with TRIM44 overexpression. Genomic and...

colorectal cancer
lung cancer
gastroesophageal cancer

Researchers at Roswell Park Receive Grants to Study New Anticancer Agent in Lung, Colorectal, and Gastrointestinal Cancers

Researchers at Roswell Park Cancer Institute have been awarded three of four grants by the National Comprehensive Cancer Network (NCCN) Oncology Research Program to evaluate and define the clinical effectiveness of the investigational compound nintedanib. Nintedanib is an investigational...

Gastroesophageal Cancer
Palliative Care

Radiation Alone Is as Effective as and Less Toxic Than Chemoradiation for Advanced Esophageal Cancer

Radiation therapy alone was found to be as effective as chemoradiation in reducing dysphagia associated with advanced esophageal cancer in the palliative setting and was less toxic, according to results of a multinational phase III trial called the Trans-Tasman Radiation Oncology Group (TROG) 03.01 ...

Gastroesophageal Cancer

Ramucirumab in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On November 5, 2014, ramucirumab (Cyramza) was approved for use...

Gastroesophageal Cancer

FDA Approves Ramucirumab in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ramucirumab was approved in April 2014 as a single agent for the treatment of...

Gastroesophageal Cancer

Customizing Surveillance Strategy in Patients With Esophageal Adenocarcinoma

A surveillance strategy for patients with esophageal adenocarcinoma treated with chemoradiation and surgery (trimodality therapy) can potentially be customized based on surgical pathology stage, according to an analysis of 518 patients with esophageal adenocarcinoma who underwent trimodality...

Gastroesophageal Cancer

High Genetic Propensity to Obesity Raises Risk of Esophageal Adenocarcinoma

“People with a high genetic propensity to obesity have higher risks of esophageal metaplasia and neoplasia than people with a low genetic propensity,” according to analyses of data from the Barrett’s and Esophageal Adenocarcinoma Genetic Susceptibility Study. “These analyses provide the strongest...

Gastroesophageal Cancer
Survivorship

Primary Surgical Therapy Results in Higher 5-Year Survival for Patients With Advanced-Stage Disease

Bucking national trends toward preserving the larynx in patients with advanced laryngeal cancer, treatment of patients for stage IV disease at Louisiana State University (LSU) Health-Shreveport were more likely to involve primary surgical therapy, including total laryngectomy, and more likely to...

Gastroesophageal Cancer

Radiotherapy Alone as Effective as Chemoradiation Therapy in Palliation of Dysphagia in Patients With Advanced Esophageal Cancer

Palliation of dysphagia associated with advanced esophageal cancer can be effectively accomplished with radiotherapy alone, without the addition of chemotherapy, according to a multinational phase III study presented at the 2015 Gastrointestinal Cancers Symposium.1 “There was no significant...

Gastroesophageal Cancer

Inhibiting the MET Pathway in Gastroesophageal Cancer: Hits and Misses

The MET pathway appears to be important in gastroesophageal cancers, but response to a targeted agent may depend on the class of drugs. A robust response to the novel small-molecule MET inhibitor AMG 337 was observed, but a monoclonal antibody targeting MET fell flat, in studies reported at the...

Gastroesophageal Cancer

Clinical Trials Actively Recruiting Patients With Esophageal Cancer

The information contained in this Clinical Trials Resource Guide includes actively recruiting observational, interventional, phase I, phase II, and phase III clinical studies for patients with newly diagnosed or recurrent esophageal cancer. All of the studies are listed on the National Institutes...

Gastroesophageal Cancer

Too Young to Have Cancer

The first inkling I had that something could be seriously wrong occurred just over a year ago, when I was suddenly inflicted with such severe heartburn it kept me awake at night. Prescriptions from my doctor for ranitidine (Zantac) and meloxicam (Mobic) not only failed to tamp down the fiery pain,...

Gastroesophageal Cancer

More Extensive Lymph Node Clearance During Surgery for Esophageal Cancer May Not Improve Survival

A population-based cohort study “indicates that more extensive lymph node clearance during surgery for esophageal cancer may not improve survival,” Maartje van der Schaaf, MD, PhD, of the Karolinska Institutet, Stockholm, and colleagues reported in the Journal of the National Cancer Institute....

Thyroid Cancer
Gastroesophageal Cancer
Lymphoma

Cancer Will Always Be Part of My Life

My first experience with cancer was when I was just 9 years old, and a lump the size of an egg popped out on the right side of my neck. A biopsy of the tumor found that it was Hodgkin lymphoma, and I was given huge doses of external-beam radiotherapy applied to my neck, chest, and underarm lymph...

Gastroesophageal Cancer

Evidence Mounts for Less-Intense Chemoradiation Therapy for Low-Risk Oropharyngeal Cancer

A new study shows that deintensification of chemoradiation therapy translates to excellent pathologic complete response rates in low-risk human papillomavirus (HPV)-associated oropharyngeal cancer.1 Patient-reported outcomes showed that side effects declined after 8 weeks. The hope is that these...

gastroesophageal cancer

ASTRO 2015: Involved-Field Irradiation for Locally Advanced Esophageal Cancer Reduces Toxicity Without Increasing Locoregional Lymph Node Recurrence

For patients with locally advanced esophageal cancer that has spread to the lymph nodes, radiation therapy that targets only the involved lymph node regions results in less toxicity without causing a statistically significant difference in locoregional lymph node recurrence, distant failure, and...

lung cancer
gastroesophageal cancer

KW-0761 May Reduce Immune System–Suppressing Treg Cells in Patients With Solid Tumors

A small phase Ia clinical trial investigating whether depleting immune cells called Tregs, which can inhibit anticancer immune responses, with KW-0761, a humanized anti-CCR4 monoclonal antibody, in patients with lung or esophageal cancer has found that the therapy dramatically reduced the number of ...

gastroesophageal cancer

Similar Survival With Salvage Surgery After Definitive Chemoradiotherapy vs Neoadjuvant Chemotherapy Followed by Esophagectomy in Esophageal Cancer

In a retrospective European study reported in the Journal of Clinical Oncology, Markar et al found that salvage esophagectomy after definitive chemoradiotherapy was associated with similar survival outcomes vs neoadjuvant chemotherapy followed by planned esophagectomy in treatment of...

solid tumors
gastroesophageal cancer

Long-Term Results of Dutch CROSS Trial Indicate Continued Survival Benefit With Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Initial results of the Dutch phase III CROSS trial showed a significant 5-year overall survival benefit with the addition of neoadjuvant chemoradiotherapy to surgery after a median 45-month follow-up in patients with squamous cell carcinoma or adenocarcinoma of the esophagus or esophagogastric...

issues in oncology
issues in oncology
gastroesophageal cancer
issues in oncology

‘Pill on a String’ Could Help Spot Early Signs of Esophageal Cancer

A “pill on a string” developed by researchers at the University of Cambridge could help doctors detect esophageal cancer at an early stage, helping them overcome the problem of wide variation between biopsies, suggests research published by Ross-Innes et al in Nature Genetics. The...

issues in oncology
gastroesophageal cancer
issues in oncology

New Molecular Diagnostic Test Predicts Progression of Barrett's Esophagus to Esophageal Cancer

Interpace Diagnostics, a subsidiary of PDI, Inc, announced new data demonstrating the clinical value of BarreGen, a molecular diagnostic test that predicts the risk of progression from Barrett’s esophagus to esophageal cancer approximately 3 to 4 years before the cancer develops. These...

colorectal cancer
solid tumors
issues in oncology
gastroesophageal cancer

AACR 2015: Long-Term, Regular Aspirin Use Modestly Decreased Cancer Risk

Long-term, regular aspirin use was associated with a modestly reduced overall risk for cancer, driven primarily by a reduction in the risk for colorectal cancers, according to research presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract 876). “Previous...

gastroesophageal cancer

More Extensive Lymph Node Clearance During Surgery for Esophageal Cancer May Not Improve Survival

A population-based cohort study indicates that “more extensive lymph node clearance during surgery for esophageal cancer may not improve survival,” van der Schaaf et al reported in the Journal of the National Cancer Institute. “These results challenge current clinical guidelines,...

solid tumors
gastroesophageal cancer

FDA Approves Ramucirumab in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

The U.S. Food and Drug Administration (FDA) today approved ramucirumab (Cyramza) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ramucirumab was approved in April 2014 as a single agent for the treatment of...

gastroesophageal cancer

Substantial Benefit of Intensive Surveillance Following Bimodality Therapy for Esophageal Cancer

In a study reported in the Journal of Clinical Oncology, Sudo et al found that many patients undergoing definitive chemoradiotherapy (bimodality therapy) for esophageal cancer can derive substantial survival benefit  from subsequent salvage surgery, supporting a practice of intensive...

head and neck cancer
gastroesophageal cancer

Study Finds Association Between Increased Esophageal COX-2 Expression and Barrett’s Esophagus, Obesity, and Smoking

Elevated esophageal mucosa cyclooxygenase-2 (COX-2) levels appear to be associated with the presence of Barrett’s esophagus as well as high waist-to-hip ratios and current tobacco smoking, according to the results of a study reported by Nguyen et al in Digestive Diseases & Sciences. These ...

issues in oncology
gastroesophageal cancer

ASTRO: Pretreatment Serum Levels of VEGF-A and TGF-β1 Predictive of Outcomes in Esophageal Cancer

Serum levels of VEGF-A and TGF-β1 may be helpful in tailoring neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma, according to research presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 10). Results of...

gastroesophageal cancer

ASTRO: Radiation Therapy Alone vs Chemoradiotherapy for Reducing Dysphagia in Advanced Esophageal Cancer

Radiation therapy alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as radiation therapy combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented at the American Society for Radiation...

head and neck cancer
gastroesophageal cancer

Tumor Downstaging After Neoadjuvant Chemotherapy Strongly Predicts Improved Outcome After Surgery in Esophageal and Esophagogastric Junction Cancer

In a European analysis reported in the Journal of Clinical Oncology, Davies et al found that pathologic tumor downstaging after neoadjuvant chemotherapy was the strongest independent predictor of overall survival in patients undergoing surgery for esophageal and esophagogastric junction...

gastroesophageal cancer

Study Helps Compare Risks of Endoscopic vs Surgical Resection for Early Esophageal Cancer

A new study published in the Journal of the National Cancer Institute by researchers at Northwestern Medicine shed new light on the risks associated with the growing popularity of endoscopic resection in the treatment of localized, early-stage esophageal cancer. Merkow et al found that the...

gastroesophageal cancer

Statin Use Associated With Decreased Risk of Barrett's Esophagus

Statin use was associated with a significantly reduced risk of developing Barrett’s esophagus, according to a new study by Nguyen et al in Gastroenterology. Obese patients experienced the greatest level of risk reduction with statin use. While statins have been associated with a reduced risk...

head and neck cancer
gastroesophageal cancer

French Phase III Trial Shows No Benefit of Neoadjuvant Chemoradiation in Stage I and II Esophageal Cancer

The effect of neoadjuvant chemoradiation therapy in early-stage esophageal cancer is not clear. In the phase III FFCD 9901 trial reported in the Journal of Clinical Oncology, Mariette et al found that neoadjuvant chemoradiation including fluorouracil (5-FU) and cisplatin did not improve R0...

solid tumors
gastroesophageal cancer

Adding Rilotumumab to First-Line Chemotherapy May Benefit Patients With Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Hepatocyte growth factor (HGF) and its receptor MET have been found to promote the proliferation, migration, and survival of tumor cells and to play a role in gastric cancer. In a phase II study reported in The Lancet Oncology, Iveson et al found evidence of benefit from adding the anti-HGF...

gastroesophageal cancer

No Overall Survival Improvement but Some Palliative Benefit With Gefitinib vs Placebo in Esophageal Cancer Progressing After Chemotherapy

In what may be the first randomized trial of systemic therapy in this setting, Dutton and colleagues evaluated gefitinib (Iressa) vs placebo in patients with esophageal cancer progressing after chemotherapy. As reported in The Lancet Oncology, the COG trial showed no survival benefit with gefitinib ...

Advertisement

Advertisement

;
Advertisement